Activation and expansion of T-cells using an engineered...

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S325000, C435S373000, C435S455000

Reexamination Certificate

active

07745140

ABSTRACT:
Provided are a system and methods for selectively inducing expansion of a population of T cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of CTLs, preferably human CTLs. In addition, T cell proliferation can be induced without the need for antigen, thus providing an expanded T cell population that is polyclonal with respect to antigen reactivity. Further provided are methods for using the system and methods to screen and identify antigens related to specific diseases or conditions, tumors, autoimmune disorders, or an infectious disease or pathogen, and to identify target molecule for research purposes, or for developing a vaccine based thereon.

REFERENCES:
patent: 5166320 (1992-11-01), Wu et al.
patent: 5190878 (1993-03-01), Wilhelm
patent: 5529921 (1996-06-01), Peterson et al.
patent: 5827642 (1998-10-01), Riddell et al.
patent: 5858358 (1999-01-01), June et al.
patent: 5888807 (1999-03-01), Palsson et al.
patent: 5962320 (1999-10-01), Robinson
patent: 5985653 (1999-11-01), Armstrong et al.
patent: 6001365 (1999-12-01), Peterson et al.
patent: 6096532 (2000-08-01), Armstrong et al.
patent: 6352694 (2002-03-01), June et al.
patent: 6355479 (2002-03-01), Webb et al.
patent: 6464973 (2002-10-01), Levitsky et al.
patent: 6534055 (2003-03-01), June et al.
patent: 6797514 (2004-09-01), Berenson
patent: 6867041 (2005-03-01), Berenson et al.
patent: 6887466 (2005-05-01), June et al.
patent: 6890753 (2005-05-01), Flyer et al.
patent: 6905681 (2005-06-01), June et al.
patent: 6905874 (2005-06-01), Berenson et al.
patent: 7175843 (2007-02-01), June et al.
patent: 2003/0147869 (2003-08-01), Riley et al.
patent: 2003/0224520 (2003-12-01), June et al.
patent: 2004/0110290 (2004-06-01), June et al.
patent: 2004/0191235 (2004-09-01), Groux et al.
patent: 2004/0241162 (2004-12-01), Berenson et al.
patent: 2005/0003484 (2005-01-01), Hirano et al.
patent: 2006/0034810 (2006-02-01), Riley et al.
patent: 2006/0121005 (2006-06-01), Berenson et al.
patent: WO 95/00642 (1995-01-01), None
patent: WO 95/03408 (1995-02-01), None
patent: WO95/33823 (1995-12-01), None
patent: WO99/36093 (1999-07-01), None
patent: WO 00/25813 (2000-05-01), None
patent: WO 02/092793 (2002-11-01), None
patent: WO 03/006632 (2003-01-01), None
patent: WO03/057171 (2003-07-01), None
patent: WO03/065977 (2003-08-01), None
Vieweg et al. Expert Opin. Biol. Ther. 2004. 4;11:1791-1801.
Britten et al. Journal of Immunological Methods. 2002, 259:95-110.
San Jose et al. Eur. J. Immunol. 1998. 28:12-21.
Groux et al., “CD3-mediated apoptosis of human medullary thymocytes and activated peripheral T cells: respective roles of interleukin-1, interleukin-2, interferon-γ and accessory cells”,Eur. J. Immunol. 23:1623-1629 (1993).
Kabelitz et al., “Life and death of a superantigen-reactive humand CD4+T cell clone: staphylococcal enterotoxins induce death by apoptosis but simultaneously trigger a proliferative response in the presence of HLA-DR+antigen-presenting cells”,International Immunology4:12, 1381-1388 (1992).
Zamai et al., “Lymphocyte binding to K562 cells: effect of target cell irradiation and correlation with ICAM-1 and LFA-3 expression”,Eur. J. Histochem. 38:1, 53-60 (1994).
Thomas, A.K., et al., “A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes,”Clinical Immunology105(3): 259-272, Dec. (2002).
Almand, et al., “Clinical Significance of Defective Dendritic Cell Differentiation in Cancer”,Clinical Cancer Research6, pp. 1755-1766, May 2000.
Bamford, et al., “The 5′ Untranslated Region, Signal Peptide, and the Coding Sequence of the Carboxyl Terminus of IL-15 Participate in Its Multifaceted Translational Control”,J. Immunol. 160, pp. 4418-4426, 1998.
Bierer et al., “T Cell Receptors: Adhesion and Signaling”,Advance Cancer Research56, pp. 49-76, 1991.
Bretscher, “The two-signal model of lymphocyte activation twenty-one years later”,Immunol. Today13, pp. 74-76, 1992.
Brodie et al., “In vivo migration and function of transferred HIV-1-specific cytotoxic T cells”,Nat. Med. 5:1, pp. 34-41, Jan. 1999.
Byun et al., “In Vitro Maturation of Neonatal Human CD8 T Lymphocytes into IL—and IL-5-Producing Cells”,J. Immunol. 153, pp. 4862-4871, 1994.
Chapoval et al., “B7-H3: A costimulatory molecule for T cell activation and IFN-γ production”,Nature Immunology2:3, pp. 269-274, Mar. 2001.
Claret et al., “Characterization of T Cell Repertoire in Patients with Graft-Versus-Leukemia After Donor Lymphocyte Infusion”,J. Clin. Invest. 100:4, pp. 855-866, Aug. 1997.
Curtsinger et al., “CD8+Memory T Cells (CD44high, Ly-6C+) Are More Sensitive than Naïve Cells (CD44low, Ly-6C−) to TCR/CD8 Signaling in Response to Antigen”,J. Immunol. 160, pp. 3236-3243, 1998.
Dahl et al., “Expression of Bcl-XLRestores Cell Survival, but Not Proliferation and Effector Differentiation, in CD28-deficient T Lymphocytes”,J Exp. Med. 191:12, pp. 2031-2037, Jun. 2000.
DeBenedette et al., “Costimulation of CD28−T Lymphocytes by 4-1BB Ligand”,J. Immunol. 158, pp. 551-559, 1997.
Deeths et al., “B7-1-dependent co-stimulation results in qualitatively and quantitatively different responses by CD4+and CD8+T cells”,Eur. J. Immunol. 27, pp. 598-608, 1997.
Deeths et al., “CD8+T Cells Become Nonresponsive (Anergic) Following Activation in the Presence of Costimulation”,J.Immunol. 163, pp. 102-110, 1999.
Dong et al., “B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion”,Nature Medicine5:12, pp. 1365-1369, Dec. 1999.
Dudley et al., “Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma”,J. Immunother. 24, pp. 363-373, 2001.
Dunbar et al., “Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood”,Current Biology8, pp. 413-416, Mar. 1998.
Fraser et al., “Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28”,Science251, pp. 313-316, Jan. 1991.
Freeman et al., “Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation”,J. Exp. Med. 192:7, pp. 1027-1034, Oct. 2000.
Gett et al., “Cell division regulates the T cell cytokine repertoire, revealing a mechanism underlying immune class regulation”,Proc. Natl. Acad. Sci.U.S.A95, pp. 9488-9493, 1998.
Gett et al., “A cellular calculus for signal integration by T cells”,Nature Immunology1:3, pp. 239-244, Sep. 2000.
Gillis et al., “Long term culture of tumour-specific cytotoxic T cells”,Nature268, pp. 154-156, Jul. 1977.
Gimmi et al., “B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2”,Proc. Natl. Acad. Sci. USA88, pp. 6575-6579, Aug. 1991.
Goodwin et al., “Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor*”,Eur. J. Immunol. 23, pp. 2631-2641, 1993.
Guinn et al., “4-1BB Cooperates with B7-1 and B7-2 in Converting a B Cell Lymphoma Cell Line into a Long-Lasting Antitumor Vaccine”,J. Immunol. 162, pp. 5003-5010, 1999.
Hansen et al., “Monoclonal Antibodies Identifying a Novel T-Cell Antigen and IA Antigens of Human Lymphocytes”,Immunogenetics10, pp. 247-260 1980.
Harding et al., “CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones”,Nature356, pp. 607-609, Apr. 1992.
Heslop

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Activation and expansion of T-cells using an engineered... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Activation and expansion of T-cells using an engineered..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Activation and expansion of T-cells using an engineered... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4161004

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.